ArticleAntimicrobial agents and chemotherapy2022
Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pooled it
- Non-Candida fungal cholecystitis - an uncommon occurrence even in the right host.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026Article
- New Perspectives on Antimicrobial Agents: Fosmanogepix.Antimicrobial agents and chemotherapy · 2026Review
- Multicenter surveillance of antifungal susceptibility of clinicalMicrobiology spectrum · 2026Article
- Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety.Investigative ophthalmology & visual science · 2026Article
- Review
- Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.npj antimicrobials and resistance · 2025Review
- In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Clinical significance and antifungal susceptibility profile of 103 clinical isolates ofJournal of clinical microbiology · 2025Article
- Review
- Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management.Pharmaceutics · 2024Review
- A Mini-Review of In Vitro Data forJournal of fungi (Basel, Switzerland) · 2024Review
- The laboratory investigation, management, and infection prevention and control ofJournal of medical microbiology · 2024Review
- Article
- Review
- Article
- The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.Mycopathologia · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.